BLCO News & Analysis

Bausch & Lomb Maintains Stock Rating Following Pipeline Data Review

H.C. Wainwright reiterated its Buy rating and $21.00 price target on Bausch & Lomb (BLCO) after reviewing new pipeline data. The Phase 2 trial of the company's dual-action eye drop did not meet its primary endpoint at Day 29, but secondary analysis data at Day 15 was strong enough to advance the candidate into a Phase 3 program in 2027. H.C. Wainwright cited this data, along with the drug's projected peak sales potential, in maintaining its positive rating.